The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Feb. 27, 11:49 AM

Slide #17. Curis Secondary Offering

Company: Curis (NASDAQ:CRIS)
Date announced: 2/24/2015
Shares Offered: 21,818,181
Date of Pricing: 2/25/2015
Price Per Share: $2.75
Secondary Offering Details: Curis, Inc. (Nasdaq:CRIS), announced today that it has commenced an underwritten public offering of shares of its common stock. In connection with this offering, Curis intends to grant the underwriters for the offering a 30-day option to purchase an additional 15% of the shares of its common stock offered in the public offering. All of the shares in the offering are to be sold by Curis. - updated 2/25 - Curis, Inc. (Nasdaq:CRIS), announced today the pricing of an underwritten registered public offering of 21,818,181 shares of its common stock at a public offering price of $2.75 per share resulting in aggregate proceeds of $60.0 million, before underwriting discounts, commissions and estimated expenses. All of the shares to be sold in the offering are to be sold by Curis. The offering is expected to close on or about March 2, 2015, subject to the satisfaction of customary closing conditions. The joint book-running managers for the offering are Cowen and Company, LLC and RBC Capital Markets and Robert W. Baird & Co. Incorporated and Roth Capital Partners, LLC are acting as co-lead managers for the offering.

Curis is engaged in the research and development of cancer therapeutics. Co. conducts its research and development programs internally and through collaborations. Co. is focused on the development of its targeted cancer drug candidates, including CUDC-907 for lymphomas and multiple myeloma and CUDC-427 for solid tumor and lymphomas. Erivedge®, an approved medicine for the treatment of advanced basal cell carcinoma, is being developed and commercialized by F. Hoffmann-La Roche Ltd and Genentech Inc. (Genentech), under collaboration between Co. and Genentech. Also, Co.'s licensee Debiopharm is conducting clinical studies of Debio 0932, a small molecule inhibitor of heat shock protein 90.
Open the CRIS Page at The Online Investor »

Company Name:  Curis Inc
Website:  www.curis.com
Sector:  Biotechnology
Number of ETFs Holding CRIS:  1
Total Market Value Held by ETFs:  $688092
Total Market Capitalization:  $326.00M
% of Market Cap. Held by ETFs:  0.21%
 

Open the CRIS Page at The Online Investor (in a new window) »

February 27, 2015    11:49 AM Eastern
Quotes delayed 20 minutes



Strong Buy (3.67 out of 4)
78th percentile
(ranked higher than approx. 78% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.